<DOC>
	<DOC>NCT00088465</DOC>
	<brief_summary>This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: - Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, - Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, - Determine the blood levels of IM olanzapine depot in patients during long-term treatment</brief_summary>
	<brief_title>Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must have schizophrenia Female patients of childbearing potential must be using a medically accepted means of contraception Patients must have completed (within 10 days) another IM olanzapine depot study if permitted by that study's protocol. Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry Female patients must not be pregnant or breastfeeding Patients must not be experiencing acute, serious or unstable medical conditions other than schizophrenia or schizoaffective disorder Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>